Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ZAI LAB LIMITED

(ZLAB)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-27 pm EST
44.88 USD   +0.92%
07:31aZai Lab Announces NDA for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China's NMPA
GL
07:31aZai Lab Announces NDA for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China's NMPA
GL
01/19Two Zai Lab Drugs Added to China's National Reimbursement Drug List
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Asian ADRs Surge Higher in Tuesday Trading

11/01/2022 | 09:44am EST


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
BILIBILI INC. -0.86% 27.78 Delayed Quote.17.26%
CANGO INC. 3.50% 1.48 Delayed Quote.13.15%
HDFC BANK LIMITED -0.10% 1614.15 Delayed Quote.-0.76%
ICLICK INTERACTIVE ASIA GROUP LIMITED -2.94% 3.96 Delayed Quote.2.86%
IQIYI, INC. -2.50% 6.24 Delayed Quote.17.74%
JIANPU TECHNOLOGY INC. 4.19% 1.99 Delayed Quote.25.16%
MOGU INC. 0.51% 2.7139 Delayed Quote.9.87%
SEA LIMITED 2.31% 68.55 Delayed Quote.31.75%
SIFY TECHNOLOGIES LIMITED -6.56% 1.71 Delayed Quote.48.50%
WNS (HOLDINGS) LIMITED -0.56% 85.39 Delayed Quote.6.75%
ZAI LAB LIMITED 0.92% 44.88 Delayed Quote.46.19%
All news about ZAI LAB LIMITED
07:31aZai Lab Announces NDA for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by Ch..
GL
07:31aZai Lab Announces NDA for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by Ch..
GL
01/19Two Zai Lab Drugs Added to China's National Reimbursement Drug List
MT
01/18Zai Lab's Qinlock, Nuzyra Added to China's National Reimbursement Drug List; Shares Ris..
MT
01/18Paratek Pharmaceuticals Says Nuzyra Added to China's National Reimbursement Drug List
MT
01/18Zai Lab Limited Announces Executive Appointments
CI
01/18Zai Lab's Qinlock, Nuzyra Listed Among China's National Reimbursement Drugs
DJ
01/18Zai Lab Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in Chin..
GL
01/18Zai Lab Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in Chin..
GL
01/18Zai Lab Limited Announces Inclusion of QINLOCK® and NUZYRA® (omadacycline) in China..
CI
More news
Analyst Recommendations on ZAI LAB LIMITED
More recommendations
Financials (USD)
Sales 2022 214 M - -
Net income 2022 -454 M - -
Net cash 2022 966 M - -
P/E ratio 2022 -9,11x
Yield 2022 -
Capitalization 4 307 M 4 307 M -
EV / Sales 2022 15,6x
EV / Sales 2023 8,78x
Nbr of Employees 1 951
Free-Float 99,7%
Chart ZAI LAB LIMITED
Duration : Period :
Zai Lab Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZAI LAB LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 44,88 $
Average target price 82,84 $
Spread / Average Target 84,6%
EPS Revisions
Managers and Directors
Ying Du Chairman & Chief Executive Officer
Rafael G. Amado President & Head-Global Oncology R&D
Billy Cho Chief Financial Officer
Ning Xu Executive VP & Head-Clinical Operations
James Yan Chief Operating Officer-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ZAI LAB LIMITED46.19%4 307
CSL LIMITED2.41%101 009
SAMSUNG BIOLOGICS CO.,LTD.-1.46%46 755
BIOGEN INC.4.75%41 772
WUXI BIOLOGICS (CAYMAN) INC.18.55%38 289
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.19.07%24 667